The world's largest manufacturer of psychiatric medication, Eli Lilly and Company, has announced its second quarter results, reporting sales were up 20 percent, worldwide. Eli Lilly reported Q2 sales reached $4.63 billion, with volume up 11 percent, led by the antidepressant drug Cymbalta and the erectile dysfunction drug Cialis.

In January, Eli Lilly acquired Cialis' maker, ICOS Corp. for $2.3 billion. The second quarter return is the first full period incorporating Cialis profits into Eli Lilly's numbers. The take-over kicked marketing and administrative expenses up 23 percent to $1.52 billion.

"We are very pleased to have delivered another quarter of strong financial results," CEO Sidney Taurel said. "Our accelerated, double-digit sales growth in this quarter was fueled by increased volume, driven by several products launched this decade, most notably Cymbalta."

"In addition, on a pro forma adjusted basis, we delivered exceptional earnings per share results by growing sales faster than cost of sales and operating expenses. We are encouraged by our outlook for the remainder of the year, and we feel confident in again raising our full-year 2007 sales and earnings guidance," Taurel added.